摘要
目的:探讨应用两种药物治疗新诊断癫痫的安全性与疗效。方法:癫痫患儿60例根据入院顺序平分为两组:治疗组与对照组各30例,对照组采用托吡酯治疗,治疗组采用拉莫三嗪治疗,所有患者均用韦氏成人智力量表中国修订版(WAIS-CR)和蒙特利尔认知评分量表(M0CA)在用药前及用药后3个月进行问卷评定。结果:治疗组治疗后与治疗前相比,言语智商、操作智和总智商明显下降(P<0.05),而对照组治疗前后上述指标改善不大(P<0.05)。治疗组治疗后与治疗前相比M0CA评分明显上升(P<0.05),而对照组治疗前后上述指标改善不大(P<0.05)。结论:与常规托吡酯预防新诊断癫痫相比,拉莫三嗪对能够更好的恢复认知功能,可提高冶疗疗效,同时安全性好。
Objective： To explore safety and effect of treating newly diagnosed epilepsy by topiramate and lamotriginc.Methods： 60 chitdren with epilepsy were equally divided into TreatmentGroup and Control Group （each 30 cases） as per admission sequence. Control Group was treated with topiramate; on the other hand. Treatment Group was treated with lamotngine.All the patients were assessed by questiormaire as per WAIS-CR and MOCA 3 months before and after drug treatment.Results： Before and after treatment. Treatment Group showed a significant decrease in language, operation and total intelligence （P 〈 0.05）; however. Control Group showed no significant increase in the above indexes （P 〈 0.05）.Moreover, before and after treatment, Treatment Group had a significant increase in MOCA score （P〈0.05）： however, Control Group showed no significant increase in the above indexes.Conclusion： Compared with via topiramate for treating newly diagnosed epilepsy, lamotrigine has a better function of restoring cognition to improve curative effect and has good safety.
出处
《中国医药导刊》
2011年第10期1746-1746,1748,共2页
Chinese Journal of Medicinal Guide
